| insulin resistance | Many people with noninsulin-dependent diabetes produce enough insulin, but their bodies do not respond to the action of insulin. This may happen because the person is overweight and has too many fat cells, which do not respond well to insulin. Also, as people age, their body cells lose some of the ability to respond to insulin. Insulin resistance is also linked to high blood pressure and high levels of fat in the blood. Another kind of insulin resistance may happen in some people who take insulin injections. They may have to take very high doses of insulin every day (200 units or more) to bring their blood glucose (sugar) down to the normal range. (09 Oct 1997) |
|---|---|
| tetracycline resistance | Nonsusceptibility of a microbe (usually a bacterium) to the action of tetracycline, which binds to the 30s ribosomal subunit and prevents the normal binding of aminoacyl-trna. (12 Dec 1998) |
| thyroid hormone resistance syndrome | <syndrome> An inherited syndrome of peripheral resistance to thyroid hormones, transmitted as an autosomal recessive trait, characterised by increased serum concentrations of thyroxine and triiodothyronine, increased thyroid hormone binding ratio, and normal to slightly increased thyroid-stimulating hormone and its response to thyrotropin-releasing hormone. The affected persons are euthyroid to slightly hypothyroid. The absence of hypermetabolism and the presence of possible hypothyroidism indicate the existence of partial resistance to the peripheral action of thyroid hormone. (12 Dec 1998) |
| thyrotropin resistance | An autosomal recessive disorder in which the thyrocytes are unresponsive to thyrotropin. Compare: pseudohypoparathyroidism. (05 Mar 2000) |
| total peripheral resistance | The total resistance to flow of blood in the systemic circuit; the quotient produced by dividing the mean arterial pressure by the cardiac minute-volume. Synonym: peripheral resistance. (05 Mar 2000) |
| trimethoprim resistance | Nonsusceptibility of a bacterium to the action of trimethoprim. (12 Dec 1998) |
| expiratory resistance | Resistance to flow of gas out of the lungs or the total resistance to flow of gas during the expiratory phase of the respiratory cycle. (05 Mar 2000) |
| kanamycin resistance | Nonsusceptibility of bacteria to the antibiotic kanamycin, which can bind to their 70s ribosomes and cause misreading of messenger RNA. (12 Dec 1998) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| akathisia, drug-induced | Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation). (12 Dec 1998) |
| antineoplastic drug | A drug that stops or slows the maturation and spread of tumour cells (benign or malignant). (09 Oct 1997) |
| maintenance drug therapy | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |